SNCA and Parkinson disease: Currently, clinical research on immunotherapy for PD remains in the early validation stage, with most studies focusing on active immunotherapy, such as PD01A and UB-312, which aim to regulate α-synuclein aggregation or restore the dopaminergic system (7, 20).